Sarepta Therapeutics, Inc. SRPT Securities Lawsuit

Company:	Sarepta Therapeutics, Inc.
Ticker Symbol:	SRPT
Class Period:	Jul-24-13 to Nov-12-13
Date Filed:	Jan-28-14
Lead Plaintiff Deadline:	Mar-29-14
Court:	District of Massachusetts
Allegations:

New York, NY: A securities class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") common stock between July 24, 2013 through November 12, 2013.

The complaint alleges that Sarepta issued a series of multiple statements concerning, among other things: (1) the prospects of the Food and Drug Administration's ("FDA") acceptance for consideration of a New Drug Application ("NDA") for eteplirsen based on Sarepta's Phase IIb study data set, and (2) the significance of that data set.

However, during a meeting on November 12, 2013, the FDA informed Sarepta that its announced, anticipated NDA filing for eteplirsen was premature. On this news, Sarepta's stock price fell from its closing price of $36.56 per share on November 11, 2013 to $13.16 per share on November 12, 2013.

If you acquired the securities of the defendants during the Class Period you may, no later than the Lead Plaintiff Deadline shown above, request that the Court appoint you as lead plaintiff through counsel of your choice. You may also choose to remain an absent class member. A lead plaintiff must meet certain requirements.

Sarepta Therapeutics, Inc. SRPT Securities Fraud Legal Help

If you have suffered from financial losses, you may qualify for damages or remedies that may be awarded in a possible Sarepta Therapeutics, Inc. securities class action lawsuit. Please click the link below to submit your complaint for a free evaluation.